Oruka Therapeutics (ORKA) Stock Price, Quote, News & History | Benzinga

Oruka Therapeutics Inc (ORKA) Stock Price, Quote, News & History

ORKANASDAQ

Trade with Public

Trade with Public

$104.86

-4.83-4.4%

At close: Aug 20, 5:00 PM EST

$104.86

N/A

After Hours: 4:00 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Dividends Compare Options Stock Report

Key Statistics

Open

$107.72

Close

$104.86

Volume / Avg.

768.89K / 1.25M

Day Range

$103.14 - $109.01

52 Wk Range

14.08 - 115.52

Market Cap

$6.94B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

59

Short Interest

17.7%

Days to Cover

8.38

Recent Oruka Therapeutics Inc News

Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million Shares

Oruka Therapeutics stock falls after hours after Fairmount sells a $300 million stake via SEC filing.

Tanya Rawat

Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday

U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Therapeutics for $10.9B. Other gaining stocks include DFTX, HIVE, SSTK, BWIN, ICCM, ORKA, CHRN, UMC, MLTX, FRVO, and SMCI.

Avi Kapoor

CommVault, Kforce, AxoGen And Other Big Stocks Moving Higher On Tuesday

U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimates. Other gainers include Kforce, Omnicell, and AxoGen.

Avi Kapoor

Oruka Therapeutics Stock Explodes As Psoriasis Data Shows 'Highly Compelling' Skin Clearance

Oruka Therapeutics shares rise as ORKA-001 shows strong psoriasis clearance rates and durable dosing potential in Phase 2a EVERLAST-A trial.

Vandana Singh

XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY, JBIO, BEAM.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-100.92M

Investing Cash Flow (TTM)

-569.86M

Financing Cash Flow (TTM)

873.85M

Free Cash Flow (TTM)

-101.15M

Capital Expenditure (TTM)

-235.00K

Net Change in Cash (TTM)

203.07M

Analyst Trends and Forecast

2

May

1

Jun

2

Jul

4

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$6.39B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

6.53

Earnings Yield % (TTM)

-1.86%

Earnings Yield % (FWD)

-1.91%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$16.79

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

$228.00K

LT Debt Repayment (TTM)

-

Total Cash

$268.47M

Debt to Equity

0.00

Issuance of Debt (TTM)

$228.00K

Repayment of Debt (TTM)

-

Key Statistics

Open

$107.72

Close

$104.86

Volume / Avg.

768.89K / 1.25M

Day Range

$103.14 - $109.01

52 Wk Range

14.08 - 115.52

Market Cap

$6.94B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

59

Short Interest

17.7%

Days to Cover

8.38

About

Sector

Health Care

Industry

Biotechnology

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modi...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Oruka Therapeutics (ORKA) stock?

A

You can purchase shares of Oruka Therapeutics (NASDAQ:ORKA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Oruka Therapeutics (ORKA) competitors?

A

Other companies in Oruka Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Oruka Therapeutics (ORKA) stock?

A

Oruka Therapeutics has a consensus price target of $87.06.

Q

What is the current price for Oruka Therapeutics (ORKA)?

A

The stock price for Oruka Therapeutics (NASDAQ: ORKA) is $104.86 last updated August 20, 2026 at 4:00 PM EDT.

Q

Does Oruka Therapeutics (ORKA) pay a dividend?

A

There are no upcoming dividends for Oruka Therapeutics.

Q

When is Oruka Therapeutics (NASDAQ:ORKA) reporting earnings?

A

Oruka Therapeutics does not have any upcoming earnings scheduled.

Q

Is Oruka Therapeutics (ORKA) going to split?

A

There is no upcoming split for Oruka Therapeutics.

Q

What sector and industry does Oruka Therapeutics (ORKA) operate in?

A

Oruka Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.